Dr Lalchandani Labs Limited has received BSE in-principle approval for its proposed rights issue and continues to advance its ₹433.31 lakh fundraising initiative through equity shares with a face value of ₹10 each. The healthcare sector company has achieved a significant milestone in its capital raising process with regulatory clearance from the stock exchange.

BSE In-Principle Approval Received

The company received BSE Limited's in-principle approval on January 16, 2026, through reference number LOD/Rights/RB/FIP/1544/2025-26. The approval permits the company to use BSE Limited's name in its Letter of Offer for the proposed rights issue of fully paid-up equity shares.

Rights Issue Framework and Compliance Requirements

The BSE approval comes with specific compliance requirements and regulatory conditions. The exchange has granted permission for listing of fully paid-up equity shares proposed to be issued on rights basis, subject to completing post-issue requirements and complying with necessary statutory, legal and listing formalities.

Previous Board Meeting Outcomes

The board of directors had convened and held its meeting on December 15, 2025, from 4:00 PM to 5:00 PM, approving the fundraising initiative through rights issue mechanism. The company had initially scheduled the board meeting for December 9, 2025, which was subsequently deferred to December 15, 2025. Following the initial approval, the company scheduled another board meeting on December 22, 2025, to finalize the specific terms of the rights issue.

Regulatory Compliance and Next Steps

The BSE approval letter outlines several key compliance requirements including fixing a record date with at least three working days advance notice to the exchange. The company must disclose and intimate the rights issue price of equity shares at least three working days prior to the record date. The exchange has emphasized that the company will be solely responsible for any consequence arising due to non-disclosure, suppression or mis-statement of information in the offer document.

The rights issue remains subject to receipt of statutory and regulatory approvals in accordance with the amended SEBI regulations and other applicable laws. All requisite regulatory approvals will be obtained as required under the applicable framework.

Dr Lalchandani Labs Limited , a prominent player in the healthcare sector, has announced significant corporate developments following a board meeting held on September 05, 2025. The company has made key decisions aimed at strengthening its governance structure and preparing for future growth.

New Independent Director Appointment

The board has approved the appointment of Mr. Mohan Lal Gandhi as a Non-Executive Independent Director for a five-year term, commencing from September 05, 2025, to September 04, 2030. This appointment is subject to necessary approvals.

Mr. Gandhi brings a wealth of experience to the board. He is a distinguished medical professional, having completed his M.B.B.S. from the University College of Medical Sciences (UCMS), New Delhi, in 1975. His career includes training at Safdarjung Hospital and holding director positions in both private and public sector companies. Notably, Mr. Gandhi has also served as the President of the Chamber of Commerce for two years, demonstrating his leadership in the business community.

Beyond his professional achievements, Mr. Gandhi is known for his philanthropic efforts, particularly in supporting underprivileged communities through hospital and educational initiatives.

Increase in Authorized Capital

In a move that signals preparation for potential future expansion, Dr Lalchandani Labs has approved an increase in its authorized capital. The company's authorized capital will be raised from Rs. 4.50 crore to Rs. 11.00 crore, representing a substantial increase of Rs. 6.50 crore. This decision is also subject to requisite approvals.

Annual General Meeting and Auditor Appointments

The board has approved the company's 8th Annual Report and scheduled the 8th Annual General Meeting for September 30, 2025, to be held in New Delhi. In line with this, the company has announced that the Register of Members and Share Transfer Books will remain closed from September 24, 2025, to September 30, 2025 (both days inclusive) for the purpose of the AGM.

Additionally, Dr Lalchandani Labs has appointed M/s. Chauhan Pradeep & Associates as Secretarial Auditors for a five-year term, covering the financial years 2025-26 to 2029-30. The same firm has also been appointed as the scrutinizer for the upcoming AGM.

These developments reflect Dr Lalchandani Labs' commitment to robust corporate governance and strategic growth. The appointment of Mr. Gandhi as an Independent Director and the increase in authorized capital position the company for potential expansion and enhanced oversight in the coming years.